Elham Hasheminasabgorji

Ms. Elham Hasheminasabgorji

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
EHElham Hasheminasabgorji
Elham Hasheminasabgorji
Jay C. JhaJay C. Jha
Jay C. Jha
The prevalence of diabetes is growing at an alarming rate with increased disability, morbidity, and often premature mortality because of the various complications of this disorder. Chronic hyperglycemia, dyslipidemia, and other metabolic alterations lead to the development and progression of macro- and microvascular complications of diabetes including cardiovascular, retinal and kidney disease. Despite advances in glucose and lipid lowering treatments, a large number of diabetic individuals develop one or more types of these complications, ultimately leading to end-organ damage over the time. Atherosclerosis is the major macro-vascular complications of diabetes and the primary underlying cause of cardiovascular disease (CVD) posing heavy burden on the health care system. In this review, we discuss the involvement of dyslipidemia in the progression of atherosclerosis by activating the pro-inflammatory cytokines and oxidative stress-related factors. In addition, we also provide information on various pharmacological agents that provides protection against diabetic atherosclerosis by reducing inflammation and oxidative stress.

15 January 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HLHolly Lee
Holly Lee
SASungwoo Ahn
Sungwoo Ahn
GGGerone A. Gonzales
Gerone A. Gonzales
NLNoemie Leblay
Noemie Leblay
EBElie Barakat
Elie Barakat
NBNizar J. Bahlis
Nizar J. Bahlis
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.

9 March 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MTMohammad Amin Khazeei Tabari
Mohammad Amin Khazeei Tabari
RMRazie Mirjalili
Razie Mirjalili
HKHooman Khoshhal
Hooman Khoshhal
ESElahe Shokouh
Elahe Shokouh
MKMohanna Khandan
Mohanna Khandan
ABAbouzar Bagheri
Abouzar Bagheri
Background and Purpose. Diabetes mellitus (DM), hyperglycemia, and hypertension can result in diabetic retinopathy (DR), which is a major cause of blindness on a global scale. Development of DR is associated with decreased endothelial cells, increased basal membrane thickness, permeation of the retinal blood barrier, and neovascularization in patients. The purpose of the present review is to provide an overview of the findings regarding applications of phytochemicals for DR treatment and could be a beneficial resource for further clinical studies and also a basis for pharmaceutical purposes for drug design. Materials and Methods. A narrative literature review was performed from electronic databases including Web of Science, PubMed, and Scopus to analyze the effects of different phytochemicals to prevent or treat oxidation, angiogenesis, and inflammation in diabetic retinopathy. The inclusion criteria were original studies, which included the effects of different phytochemicals on diabetic retinopathy. The exclusion criteria included studies other than original articles, studies which assessed the effects of phytochemicals on nondiabetic retinopathy, and studies which used phytochemical-rich extracts. Results and Conclusions. Studies have shown that increased levels of inflammatory cytokines, angiogenic, and oxidative stress factors are involved in the progression and pathogenesis of DR. Therefore, phytochemicals with their anti-inflammatory, antiangiogenic, and antioxidant properties can prevent DR progression and retinal damage through various cellular mechanisms. It is also shown that some phytochemicals can simultaneously affect the inflammation, oxidation, and angiogenesis in DR.

1 June 2023 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
EHElham Hasheminasabgorji
Elham Hasheminasabgorji
MMMohammad Amir Mishan
Mohammad Amir Mishan
MTMohammad Amin Khazeei Tabari
Mohammad Amin Khazeei Tabari
ABAbouzar Bagheri
Abouzar Bagheri
Background: There is an unmet need to improve the diagnosis of cancer with precise treatment strategies. Therefore, more powerful diagnostic, prognostic, and therapeutic biomarkers are needed to overcome tumor cells. microRNAs (miRNAs, miRs), as a class of small non-coding RNAs, play essential roles in cancer through the tumor-suppressive or oncogenic effects by post-transcriptional regulation of their targets. Many studies have provided shreds of evidence on aberrantly expressed miRNAs in numerous cancers and have shown that miRNAs could play potential roles as diagnostic, prognostic, and even therapeutic biomarkers in patients with cancers. Findings have revealed that miR-638 over or underexpression might play a critical role in cancer initiation, development, and progression. However, the mechanistic effects of miR-638 on cancer cells are still controversial. Conclusion: In the present review, we have focused on the diagnostic, prognostic, and therapeutic potentials of miR-638 and discussed its mechanistic roles in various types of cancers.

20 January 2020 in Iranian Journal of Science and Technology, Transactions A: Science
Verified
Journal Article
Closed access
PDF file
ACAbasalt Hosseinzadeh Colagar
Abasalt Hosseinzadeh Colagar
EHElham Hasheminasabgorji
Elham Hasheminasabgorji
MMMaryam Mohadjerani
Maryam Mohadjerani
FSFarshad Sohbatzadeh
Farshad Sohbatzadeh
HKHossein Karami
Hossein Karami

26 May 2025 in PHYTONutrients
Verified
Journal Article
Open access
PDF file
EHElham Hasheminasabgorji
Elham Hasheminasabgorji
MTMohammad Amin Khazeei Tabari
Mohammad Amin Khazeei Tabari
ABAbouzar Bagheri
Abouzar Bagheri
This systematic review highlights the pivotal functions of ginsenosides in cancer treatment through miRNA regulation. Ginsenosides, bioactive herbal compounds derived from ginseng, exhibit significant anti-cancer properties through mechanisms including inhibition of cell proliferation, epithelial-to-mesenchymal transition (EMT), metastasis, invasion, and induction of autophagy and apoptosis. MicroRNAs (miRNAs), small non-coding RNAs, play critical roles in gene regulation and have emerged as potential diagnostic, prognostic, and therapeutic targets in various cancers. Ginsenosides influence miRNA expression, underexpressing oncogenic miRNAs and overexpressing tumor suppressor miRNAs, thereby exerting their anti-cancer effects. The literature review covered studies from 2011 to 2021 sourced from PubMed, Scopus, Cochrane Library, and Web of Science, adhering to the PRISMA guidelines. Eligible studies were screened, resulting in the selection of 26 preclinical studies. These studies demonstrate that ginsenosides modulate the expression of various miRNAs, contributing to anti-tumorigenic activities across different cancer types, including glioma, non-small cell lung cancer, breast cancer, acute leukemia, hepatocellular carcinoma, ovarian cancer, medulloblastoma, prostate cancer, liver cancer, oral squamous cell carcinoma, retinoblastoma, and gallbladder cancer. By influencing miRNA pathways, ginsenosides can inhibit tumor growth, migration, invasion, and induce apoptosis, highlighting their therapeutic potential in oncology.